AKAN
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Akanda Corp, under the ticker AKAN, receives a Neutral rating within the current framework. The composite score of 35.1 and a conviction of 3 out of 5 align the stock with its respective rating band. This rating reflects a balance among the four pillar categories, with regulatory factors taking the forefront, contributing most significantly, while editorial input trails. Market conditions currently provide minimal support due to an absence of reliable pricing information, and fundamentals reflect the company's constrained financial state, evident by pedestrian scores in factors like cash runway.
Analyzing the core data, Akanda's revenue growth year-over-year demonstrates a commendable upward trajectory, evidencing resilience despite stretched financial conditions. However, substantial challenges lie in negative gross and operating margins, which undeniably hinder profitability. The lack of net income and a notable EBITDA deficit compound concerns of fiscal sustainability, calling attention to the company's high cash burn ratio against modest market capitalization. With regulatory filings providing scant indication of future developments, adherence to timelines remains crucial in guiding future evaluations.
Regulatory factors serve as the primary catalyst in Akanda's potential fortification, where compliance and enforcement metrics showcase a strong jurisdictional foundation within the United States. Monitoring the regulatory landscape for any shifts in posture or new enforcement mechanisms will be critical for Akanda. This ongoing vigilance may deliver an important signal for future strategic adjustments should regulatory dynamics evolve, thus necessitating close observation for any subsequent assessments.
- Headquarters
- 1A, 1B LEAROYD ROAD, NEW ROMNEY, X0, TN28 8XU
- Phone
- 442034889514
- Auditor
- with our independent registered public accounting firm
- SEC CIK
- 1888014
- Website
- Company website
- Market cap
- $5.4M
- Enterprise value
- $19.1M
- Price to book
- 2.21
- Price to sales
- 20.83
- EV / EBITDA
- -0.80
- Revenue (TTM)
- $258K
- Gross profit (TTM)
- $-156K
- EBITDA
- $-4.7M
- Operating margin
- -1353.3%
- Profit margin
- 0.0%
- Rev growth YoY
- 21.9%
- Return on equity
- -60.9%
- Return on assets
- -44.1%
- EPS (TTM)
- $-15065.55
- Shares outstanding
- 0.5M
- Insider ownership
- 0.6%
- Institutional ownership
- 1.9%
- Beta
- 14.16
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Annual report
- Latest 10-K
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for AKAN (AKAN)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for AKAN (AKAN), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Risk Elevated. Headwinds: deep drawdown. (0 bullish signals, 2 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for AKAN are maintained by Cannabis Investor News and refreshed throughout the trading day.